"
Du er her: Forside > Oslo Axess - Unoterte - Warrants - Derivater > Cortendo
Cortendo
Fast bucks
06.03.2000 22:49
#677

Endre
Re caligula , jeg endrer overskrivt da den førre var missvisende, såg ikke at den var notert !

Jeg søker litt info om det svenske selskapet Cortendo på den unoterte listen .

http://www.cortendo.se

De har forsket frem en medisin mot Metaboliskt syndrom.
Medisinen heter Normocort

Cortendo’s first development product – Normocort ® – is a completely new approach to the treatment of Metabolic Syndrome, which includes type II diabetes, and affects an estimated 25% of adults in the developed countries.

I info fra DNB markets står bla. følgande:

Case conclusion

1)A pharmaceutical R&D company with blockbuster ptential.

2)Normocort for Metabolic Syndrome:
->New type of approach to treat deadly combination of diseases
->Normocort has potential for USD muli-billion sales

3)solid patent protection

4)approval and marketing of drug in 2004


the company has doubling potential and more
->The comp. is interesting now, not in four years
->Venture investment
->possible IPO in fall 2000

..........................

Metabolic syndrome:
->A serious conditiondefined to be the association of a number of diseases and risk factors ; obesity, dyslipidaemia, hypertension and insulin resistance/ type II diabetes
-> 25% of the adult population(125 mil) in developed countries has disorders related to metabolic syndrome
->Stimulated by long term exposure to elevated levels og cortisol results in a significant increase in the amount of visceral fat - abdominal obesity
-cortendo believes this to be the trigger mechanism for the disorders related to metabolic syndrome.

patent solution
-> solid patent protection
->1 st pat. for the concept of normalazing cortisol syntesis as a treatment for metabolic syndrome and related disorders was filed in 1994
->approved in the USA and Australia
-> Filed in the EU

Patent exp. in 2014

time line - Normocort

Phase I - healty Volunteers Q1 00 - Q2 00
Phase IIA- Dose findings (50 patients) Q1 00-Q3 00
Phase IIB-Efficancy (200Patients) Q3 00 -Q2 01

PhaseIII - last phase (1500 patients) Q2 01 - Q2 03
Approval - Q2 04

Share structure

Outstanding shares 2 817 000
Privateplacement (meditor/statoil/wilhemsen) 235 000
Outstanding shares 3 052 000

Share ownership
Mårin Per 19.4%
Nordbanken 13.6%
Medicis 9.5%
SEB 4.8 %
Spetalen Egil 4.8%
Mårin konsult AB 4.6%
Met syndr I gbg AB 4.3%
Kindem ,jan sverre 3.8%
Urke Eldar 3.3%
DELPHI NORDEN 2.0 %
SPETALEN ØYSTEIN STRAY 1.8%
Østholm ivan 1.7%
Sweebank Markets 1.5 %
Foreningsbanken 1.1%
Tycoon Industri as 1.1 %
Skogan gård 1.0 %
WivelstadDag Arne 0.9 %
SPETALEN EIVIND 0.9 %
DELPHI VEKST 0.9%
Bratz Gjørn Olaf 0.8 %
Bache Christian 0.7%
Caico Investments Ldt 0.7 %
Torstein Tvenge 0.7 %
Solon AS 0.7 %
Other 15.5 %

Noen som vet noe mer om dette selskap ?


Mvh




Stocktalk.no eies av MarketMind AS
Adresse: Thunesvei 2, 0274 Oslo Tlf: 21 07 50 08 Email: st [at] stocktalk.no Orgnr: 979 175 027 MVA
Kontakt oss | Hjelp | Regler | Sett som startside | Legg til favoritter © 2008 Vestover AS